Rituximab, high-dose methotrexate plus orelabrutinib as induction therapy in newly diagnosed primary central nervous system lymphoma.
Zhao SH, Zhu ZM, Yang T, Gao D, Liu LH, Yang W, Wang XB, Zhao YX, Li M, Gao YN, Ma RJ, Yang Y, Li HP, Li L, Ao XL, Xiao XB, Hu CL, Yuan SZ, Ding Y, Chen XL, He JX, Liu Y, Huang WR.
Zhao SH, et al. Among authors: zhu zm.
Leukemia. 2025 Jul 12. doi: 10.1038/s41375-025-02658-8. Online ahead of print.
Leukemia. 2025.
PMID: 40652061
No abstract available.